 - Diagnosed or treated for malignancy other than the indication under study except for: a Adequately treated non-melanoma skin cancer or lentigo maligna, curatively treated in-situ cancer without evidence of disease; b Malignancy treated with curative intent and with no known active disease present for 3 years before the first dose of ibrutinib 